Literature DB >> 16516560

Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist.

Lawrence A Leiter1, David Fitchett.   

Abstract

Type 2 diabetes and cardiovascular disease are inextricably linked. Patients with type 2 diabetes are at increased risk of cardiovascular events and mortality. However, controlling blood glucose, which until recently had often been the focus of the diabetologist, is only one component of optimal cardiovascular risk reduction. Vascular protection of the patient with diabetes also includes management of hypertension and dyslipidaemia and lifestyle changes such as smoking cessation. Now both cardiologists and diabetologists need to optimise all components of vascular protection, including glycaemic control, in patients with diabetes. An elevated blood glucose is predictive of poor outcomes in patients with acute coronary syndromes, even if frank diabetes is not present. Early control of hyperglycaemia should be achieved: a strategy that results in improved outcomes. More than two-thirds of patients with coronary artery disease (CAD) have abnormal glucose regulation, which is a predictor of poor outcome. Therefore, the presence of diabetes (and/or glucose intolerance) should be routinely screened for in cardiac patients on admission to hospital. Early identification and treatment of CAD in patients with diabetes is important for optimal prevention of cardiovascular events. However, screening all diabetes patients for CAD is not feasible, and selection of patients for non-invasive cardiac testing remains a challenge for both the diabetologist and cardiologist. Optimal care of diabetic and cardiac patients requires a multidisciplinary team approach, with key roles for the cardiologist and diabetologist.

Entities:  

Mesh:

Year:  2006        PMID: 16516560     DOI: 10.1016/j.atherosclerosissup.2006.01.006

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  2 in total

1.  Molecular mechanisms of hyperglycemia and cardiovascular-related events in critically ill patients: rationale for the clinical benefits of insulin therapy.

Authors:  Samer Ellahham
Journal:  Clin Epidemiol       Date:  2010-12-12       Impact factor: 4.790

Review 2.  Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors.

Authors:  L Romayne Kurukulasuriya; James R Sowers
Journal:  Cardiovasc Diabetol       Date:  2010-08-30       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.